Deepu Madduri, MD | Authors


Deepu Madduri, MD, on the Design of the Phase 1b/2 CARTITUDE-1 Trial

January 12, 2021

The goal of the CARTITUDE-1 study was to evaluate the use of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) chimeric antigen receptor T-cell therapy in heavily pretreated patients with relapsed or refractory multiple myeloma.